ZIPRASIDONE HYDROCHLORIDE LOADED NANOSTRUCTURED LIPID CARRIERS (NLCS) FOR INTRANASAL DELIVERY: OPTIMIZATION AND IN VIVO STUDIES
Objective: The present study was an attempt to systemically deliver the most desirable schizophrenia drug, ziprasidone hydrochloride (ZRS) via the intranasal route using nanostructured lipid carrier (NLC) approach.
Methods: The desired ZRS loaded NLCs were developed using central composite statistical design and the developed formulation was monitored for improving ZRS bioavailability and their brain targeting efficacy.
Results: Pharmacokinetic studies revealed a 10 fold increase (ZRS blood-brain ratio) for NLCs administered through nasal route (in comparison to intravenous route). Similarly, the concentration of ZRS (in the brain) delivered via nasal route exhibits 4 fold increment at all-time points.
Conclusion: Therefore, the obtained results suggest a potential nose to brain transport of loaded ZRS by effective bypassing of the Blood-Brain Barrier (BBB).
2. Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence or trans-diagnostic issue? Schizophram Bull 2016;22:240–4.
3. Koutsouleris N, Meisenzahl EM, Borgward S, Riecher Rossler A, Frodl T, Kambeitz J, Kohler Y, et al. Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Brain 2015;138:2059–73.
4. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into the direct nose to brain delivery: current status and future perspective. Drug Delivery 2014;21:75-86.
5. Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed 2014;9:2241-57.
6. Husean IY, Rahman Al-obaidi IRAA. Optimizing nasal for optimizing nasal formulation for the prevention of serious infections caused by simulation for prevention of serious infections caused by mrsa. Int J Pharm Pharm Sci 2014;7:496-503.
7. Pagar SA, Shinkar DM, Saudagar RB. Development and evaluation of in situ nasal mucoadhesive gel of metoprolol succinate by using 32 full factorial design. Int J Pharm Pharm Sci 2014;6:218-23.
8. Lampel A, Ulijn RV, Tuttle T. Guiding principles for peptide nanotechnology through directed discovery. Chem Soc Rev 2018;47:3737-58.
9. Gordillo Galeano A, Mora Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 2018;133:285-308.
10. Patil TS, Deshpande AS. Nanostructured lipid carriers-based drug delivery for treating various lung diseases: a state?of?the?art review. Int J Pharm 2018;547(Suppl 2):209-25.
11. Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers–a systematic review of in vitro data. Eur J Pharm Biopharm 2014;87:1-8.
12. Juven Wetzler A, Fostick L, Cwikel Hamzany S, Balaban E, Zohar J. Treatment with ziprasidone for schizophrenia patients with OCD. Eur Neuropsychopharmacol 2014;24:1454-62.
13. Devkar TB, Tekade AR, Khandelwal KR. Surface engineered nanostructured lipid carriers for an efficient nose to brain delivery of ondansetron HCl using delonix regia gum as a natural mucoadhesive polymer. Colloids Surf B 2014;122:143-50.
14. Singh SK, Dadhania P, Vuddanda PR, Jain A, Velaga S, Singh S. Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetics and behavioral assessment. RSC Adv 2016;6:2032-45.
15. Abdelwahab SI, Sheikh BY, Taha MM, How CW, Abdullah R, Yagoub U, et al. Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomed 2013;8:2163-72.
16. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, et al. Strategy for effective brain drug delivery. ?Eur J Pharm Sci 2010;40:385-403.
17. Naseri N, Valizadeh H, Zakeri Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 2015;5:305-13.
18. Shah B, Khunt D, Bhatt H, Misra M, Padh H. Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: risk assessment and QbD based optimization. J Drug Delivery Sci Technol 2016;33:37-50.
19. Malik DS, Kaur G. Nanostructured gel for topical delivery of azelaic acid: Designing, characterization, and in vitro evaluation. J Drug Delivery Sci Technol 2018;47:123-36.
20. Butani S, Shah T, Parmar K, Rajput A. Development of rizatriptan benzoate microspheres for the nose to brain targeting. Int J Appl Pharm 2016;8:69-74.
21. Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Delivery 2016;23:1326-34.
22. Galgatte UC, Kumbhar AB, Chaudhari PD. Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Delivery 2014;21:62-73.
23. Sood S, Jain K, Gowthamarajan K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf B 2014;113:330-7.
24. Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. Chitosan coated nanostructured lipid carriers for the brain delivery of proteins by intranasal administration. Colloids Surf B 2015;134:304-13.
25. Shah B, Khunt D, Misra M, Padh H. Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: formulation, physicochemical and pharmacokinetic consideration. Eur J Pharm Sci 2016;91:196-207.
26. Gabal YM, Kamel AO, Sammour OA, Elshafeey AH. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int J Pharm 2014;473:42-57.
27. Kajal S Jadhav, Kiran B Erande. Solubility enhancement and formulation of fast dissolving tablets of ziprasidone hydrochloride. Int J Res Pharm Chem 2016;6:675-83.
28. Kaur N, Sharma K, Bedi N. Topical nanostructured lipid carrier-based hydrogel of mometasone furoate for the treatment of psoriasis. Pharm Nanotechnol 2018;6:133-43.
29. Jain K, Sood S, Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Delivery 2015;22:940-54.
30. Khan A, Imam SS, Aqil M, Ahad A, Sultana Y, Ali A, et al. Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. Mol Pharm 2016;13:3773-82.
31. Li F, Weng Y, Wang L, He H, Yang J, Tang X. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm 2010;393:204-12.
32. Dhuria SV, Hanson LR, Frey II WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73.
This work is licensed under a Creative Commons Attribution 4.0 International License.